Filed under: Uncategorized | Tagged: antagonist, CCR9, CCX-025, CCX025 CCR-9, ChemoCentryx, phase I
ChemoCentryx initiate Phase I trial of CCR9 antagonist CCX025
Posted on October 15, 2008 by crimsoncanary
Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
Calendar
Blogroll
Blog at WordPress.com. Theme: Digg 3 Column by WP Designer
